Overview and Scope
Xerostomia therapeutics refer to treatments and medications used to manage dry mouth, a condition characterized by reduced saliva production. These therapies aim to alleviate symptoms such as difficulty swallowing and tasting, as well as prevent dental issues.
Sizing and Forecast
The xerostomia therapeutics market size has grown strongly in recent years. It will grow from $2.04 billion in 2023 to $2.14 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increasing incidences of xerostomia in the geriatric population, research and development of efficient products for xerostomia, growing awareness about xerostomia-related products, increasing of medical conditions, and rising prevalence of chronic diseases.
The xerostomia therapeutics market size is expected to see strong growth in the next few years. It will grow to $2.65 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to easy availability of cost-effective medications in the market, increased prevalence of oral health conditions, rising awareness among healthcare practitioners, government initiatives, and increased medication use. Major trends in the forecast period include artificial saliva and saliva substitutes, technological advancements and product innovations, personalized medicine and targeted therapies, telehealth and remote monitoring, and rise of non-invasive therapies.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report
Segmentation & Regional Insights
The xerostomia therapeutics market covered in this report is segmented –
1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets
3) By End-User: Adult, Pediatric
North America was the largest region in the xerostomia therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp
Major Driver Impacting Market Growth
The increasing adoption of chemotherapy in cancer treatment is expected to propel the growth of xerostomia therapeutics market going forward. Chemotherapy in cancer treatment refers to the use of powerful medications which is to kill or slow the growth of cancer cells. The rising acceptance of chemotherapy in cancer treatment is mainly due to its effectiveness in specifically targeting and eradicating cancerous cells throughout the body. Xerostomia therapeutics include saliva-stimulating medications or mouth rinses that improve saliva production and enhance taste perception, making it easier for patients to eat and maintain adequate nutrition. For instance, in the January 2022, according to the National Cancer Institute, a US based government agency, estimated that there are 18.1 million cancer survivors in the United States which amounts to 5.4% of the total population. By 2032, there will be 22.5 million cancer survivors worldwide, a 24.4% increase from the current estimate. Therefore, the increasing adoption of chemotherapy in cancer treatment is driving the growth of the xerostomia therapeutics market.
Key Industry Players
Major companies operating in the xerostomia therapeutics market are Bayer AG, 3M Company, GlaxoSmithKline plc, Colgate-Palmolive Company, Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Cipla Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Synedgen Inc., Sunstar Suisse S.A., Advanz Pharma Corp., Pharmascience Inc., Mission Pharmacal Company, Dentaid Ltd. , Cyclacel Pharmaceuticals Inc., Parnell Pharmaceuticals Holdings Ltd., Teva Pharmaceutical Industries Ltd., Forward Science Holding Inc., ICPA Health Products Ltd., CCMed Ltd., Bio Cosmetics Laboratories S.L., Quest Products LLC, Acacia Pharma, Saliwell Limited, OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc
The xerostomia therapeutics market report table of contents includes:
1. Executive Summary
2. Xerostomia Therapeutics Market Characteristics
3. Xerostomia Therapeutics Market Trends And Strategies
4. Xerostomia Therapeutics Market – Macro Economic Scenario
5. Global Xerostomia Therapeutics Market Size and Growth
.
.
.
32. Global Xerostomia Therapeutics Market Competitive Benchmarking
33. Global Xerostomia Therapeutics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Xerostomia Therapeutics Market
35. Xerostomia Therapeutics Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
